Question to Daniel if I may. Perhaps for the next presentation if the answer will take too long here.
I am interested in your thoughts re Bisantrene vs liposomal Doxorubicin. As I understand it they both have marked reduced cardio toxicity compared to standard and are both well advanced in the clinic. I would value your thoughts as to why Bisantrene may be expected to be better and why oncologists would swap one for the other on a new trial design.
thanks
-
- There are more pages in this discussion • 8,166 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
-0.040(3.23%) |
Mkt cap ! $208.4M | |||
| Open | High | Low | Value | Volume |
| $1.24 | $1.24 | $1.20 | $103.7K | 85.92K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 12091 | $1.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 9720 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| RAC (ASX) Chart |